Source:http://linkedlifedata.com/resource/pubmed/id/10901292
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2000-11-2
|
pubmed:abstractText |
Monoalkyl ether lipid analogues of foscarnet (phosphonoformate, PFA) exhibit substantially greater in vitro antiviral activity than unmodified PFA against human immunodeficiency virus type 1 (HIV-1). Our previous studies indicate that the length of the alkyl chain must be 14-22 carbons for optimal antiviral activity. To further evaluate the structure-activity relationship, we prepared 1-O-octadecyl-sn-glycerol analogues of PFA with various substitutions at the sn-2 position of glycerol and determined the effect of structure on in vitro antiviral activity and selectivity against HIV-1 in MT-2 and CD4-expressing HeLa cells (HT4-6C). We also studied combinations of zidovudine with PFA, 1-O-octadecyl-2-O-methyl-sn-glycero-3-PFA, or 1-O-octadecyl-sn-glycero-3-PFA and calculated their combination index values against HIV-1 in HT4-6C cells. Alkyl substitutions of one to four carbons at the sn-2 position of glycerol showed optimal antiviral activity. Both alkyl ether lipid analogues were strongly synergistic with zidovudine over a wide range of drug ratios and concentrations. 1-O-octadecyl-sn-glycerol analogues of PFA have selective antiviral properties and warrant further evaluation as potential antiretroviral drugs.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antiviral Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Carriers,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Foscarnet,
http://linkedlifedata.com/resource/pubmed/chemical/Liposomes,
http://linkedlifedata.com/resource/pubmed/chemical/Zidovudine
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0956-3202
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
11
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
213-9
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:10901292-Antiviral Agents,
pubmed-meshheading:10901292-Drug Carriers,
pubmed-meshheading:10901292-Drug Combinations,
pubmed-meshheading:10901292-Drug Synergism,
pubmed-meshheading:10901292-Foscarnet,
pubmed-meshheading:10901292-HIV-1,
pubmed-meshheading:10901292-HeLa Cells,
pubmed-meshheading:10901292-Humans,
pubmed-meshheading:10901292-Liposomes,
pubmed-meshheading:10901292-Viral Plaque Assay,
pubmed-meshheading:10901292-Virus Replication,
pubmed-meshheading:10901292-Zidovudine
|
pubmed:year |
2000
|
pubmed:articleTitle |
In vitro anti-HIV-1 activity of sn-2-substituted 1-O-octadecyl-sn-glycero-3-phosphonoformate analogues and synergy with zidovudine.
|
pubmed:affiliation |
Department of Medicine, Veterans Affairs Medical Center and the University of California, San Diego, La Jolla, USA. khostetler@ucsd.edu
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't
|